292 related articles for article (PubMed ID: 24875464)
1. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
Vaidhyanathan S; Mittapalli RK; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
Mittapalli RK; Vaidhyanathan S; Dudek AZ; Elmquist WF
J Pharmacol Exp Ther; 2013 Mar; 344(3):655-64. PubMed ID: 23249624
[TBL] [Abstract][Full Text] [Related]
3. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
[TBL] [Abstract][Full Text] [Related]
4. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
5. Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.
Vaidhyanathan S; Wilken-Resman B; Ma DJ; Parrish KE; Mittapalli RK; Carlson BL; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2016 Feb; 356(2):251-9. PubMed ID: 26604245
[TBL] [Abstract][Full Text] [Related]
6. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
7. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
Roskoski R
Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
[TBL] [Abstract][Full Text] [Related]
8. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
[TBL] [Abstract][Full Text] [Related]
9. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
[TBL] [Abstract][Full Text] [Related]
10. Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Mohammad AS; Parrish KE; Mladek AC; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2019 Mar; 368(3):446-461. PubMed ID: 30622172
[TBL] [Abstract][Full Text] [Related]
11. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA
Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292
[TBL] [Abstract][Full Text] [Related]
12. Trametinib in metastatic melanoma.
Chopra N; Nathan PD
Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
[TBL] [Abstract][Full Text] [Related]
13. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
Wang T; Agarwal S; Elmquist WF
J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
[TBL] [Abstract][Full Text] [Related]
14. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
16. Trametinib for the treatment of melanoma.
Alluri N; Jimeno A
Drugs Today (Barc); 2013 Aug; 49(8):491-8. PubMed ID: 23977666
[TBL] [Abstract][Full Text] [Related]
17. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
18. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
19. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
20. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
